Login to Your Account



Clinic Roundup


Tuesday, October 29, 2013
• Clovis Oncology Inc., of Boulder, Colo., reported interim findings from the Phase I dose-escalation portion of its ongoing Phase I/II study of CO-1686, an oral, targeted covalent inhibitor of mutant forms of the epidermal growth factor receptor (EGFR), for the treatment of non-small-cell lung cancer (NSCLC) in patients with initial activating EGFR mutations and the dominant resistance mutation T790M.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription